Valeant Stellaris Elite ophthalmic surgical platform CE Mark'd

Valeant Pharmaceuticals' (NYSE:VRX) Bausch + Lomb unit declares CE Mark certification for the Stellaris Elite Vision Enhancement System, its next-generation ophthalmic surgical platform. The product includes Vitesse, a hypersonic open-port vitrectomy (surgical procedure to remove vitreous humor from the eye) system.

CEO Joseph Papa says, "We're pleased to bring the Stellaris Elite Vision Enhancement System, including the cutting-edge Vitesse technology, to the greater European market. Because this surgical platform offers the opportunity to constantly add inventive upgrades and improvements, it allows surgeons to modify their systems and expand their capabilities as their requirements evolve without having to invest in a new surgical system."